Orally consumable cannabinoid composition including lecithin
The present invention relates to a pharmaceutical composition comprising non-decarboxylated Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
1. An orally consumable cannabinoid composition comprising:
tetrahydrocannabinol (THC);
lecithin;
resveratrol;
at least small molecule selected from of the group consisting of Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), and combinations thereof, and wherein the at least one small molecules inhibits cytochrome p450 enzyme metabolism of the tetrahydrocannabinol in vivo.